
## Prarthana Thiagarajan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6880643/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Aspirin and NSAIDs; benefits and harms for the gut. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 197-206.	2.4	23
2	Narrow band imaging and serology in the assessment of premalignant gastric pathology. Scandinavian Journal of Gastroenterology, 2018, 53, 1611-1618.	1.5	23
3	Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges. Journal of Clinical and Experimental Hepatology, 2019, 9, 515-521.	0.9	23
4	The hepatitis C revolution part 1. Current Opinion in Infectious Diseases, 2015, 28, 563-571.	3.1	17
5	Metabolic Imaging in Non-Alcoholic Fatty Liver Disease: Applications of Magnetic Resonance Spectroscopy. Journal of Clinical Medicine, 2021, 10, 632.	2.4	7
6	Mapping transactional analysis to clinical leadership models. British Journal of Hospital Medicine (London, England: 2005), 2019, 80, 600-604.	0.5	6
7	Tipping the Balance: Benefits and Risks of Aspirin in Chemoprevention of Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 1-8.	0.5	2
8	The Golden 24 Hours: Checklist Bundle Improves Quality of Acute Care for Patients with Decompensated Cirrhosis and Reduces 30-Day Mortality. Journal of Hepatology, 2016, 64, S281.	3.7	2
9	Analysis of genotyping for predicting liver injury marker, procollagen <scp>III</scp> in persons at risk of nonâ€alcoholic fatty liver disease. Liver International, 2018, 38, 1832-1838.	3.9	2
10	Detecting chronic liver disease: are liver function tests the solution?. British Journal of Hospital Medicine (London, England: 2005), 2020, 81, 1-8.	0.5	2
11	Why is There a Change in Patterns of GE Cancer?. Recent Results in Cancer Research, 2012, 196, 115-140.	1.8	2
12	PWE-090ÂDoes my patient–s normal liver biopsy mean they won't develop liver disease?. Gut, 2015, 64, A251.2-A252.	12.1	0
13	The hepatitis C revolution part 2. Current Opinion in Infectious Diseases, 2015, 28, 572-575.	3.1	0